Gottfried E. Konecny, MD

Articles

Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian Cancer

April 30th 2024

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

Dr Konecny on PROs With Mirvetuximab Soravtansine in Advanced Ovarian Cancer

April 25th 2024

Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.

Dr Konecny on the MIRASOL trial and Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

March 26th 2024

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Konecny on the Indications for PARP Inhibitors in Recurrent Ovarian Cancer

May 29th 2019

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Konecny on Response to PARP Inhibitors in Ovarian Cancer

August 3rd 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

July 17th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian Cancer

June 7th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Konecny on the Use of PARP Inhibitors in Patients With Ovarian Cancer

May 29th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.